Hikma receives approval for thiotepa injection in the US

London, 15 July 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has it has received approval from the U.S. Food and Drug Administration (“FDA”) for its supplemental Abbreviated New Drug Application (“sANDA”) for thiotepa for injection USP, 15mg/vial.

Press Release Product 15 July 2015

Thiotepa is indicated for the palliation of a wide variety of neoplastic diseases, with the most consistent results seen in tumors related to adenocarcinoma of the breast and ovary. It will be the second product previously marketed by Bedford Laboratories to be launched by Hikma in the United States. Thiotepa is currently on the FDA’s Drug Shortages list and Hikma has the only approved active US ANDA.

Said Darwazah, Chairman and CEO of Hikma said, “We are making good progress with the transfer of the Bedford products to our manufacturing facilities, leveraging our strong R&D, regulatory and manufacturing capabilities. Thiotepa is used in the treatment of a variety of cancers. It has been on shortage in the US for several years and we are very pleased to be able to provide a resolution to this critical situation."

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.